1-(tert-butoxycarbonyl)-3-methyl-2,3-dihydro-1H-quinolin-4-one | 179899-24-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 1-(tert-butoxycarbonyl)-3-methyl-2,3-dihydro-1H-quinolin-4-one
• 英文别名: 1-tert-butyloxycarbonyl-1,2,3,4-tetrahydro-3-methyl-4-quinolinone；Tert-butyl 3-methyl-4-oxo-1,2,3,4-tetrahydroquinoline-1-carboxylate；tert-butyl 3-methyl-4-oxo-2,3-dihydroquinoline-1-carboxylate
• CAS: 179899-24-2
• 化学式: C₁₅H₁₉NO₃
• 分子量: 261.321
• InChiKey: GDCIBEYCLNBFEO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  46.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-(tert-butoxycarbonyl)-3-methyl-2,3-dihydro-1H-quinolin-4-one 、 ammonium chloride 在 palladium-carbon 作用下， 以 sodium borohydrid 、 乙酸乙酯 为溶剂， 以104 mg (95%)的产率得到1-tert-butyloxycarbonyl-1,2,3,4-tetrahydro-3-methylquinoline
  参考文献：
  名称：

  Steroid receptor modulator compounds and methods

  摘要：

  披露了对类固醇受体具有高亲和力、高选择性调节剂的非类固醇化合物。还披露了包含这些化合物的药物组合物、使用所披露的化合物和组合物治疗需要类固醇受体激动剂或拮抗剂治疗的患者的方法，以及在制备这些化合物中有用的中间体和制备类固醇受体调节剂化合物的过程。

  公开号：

  US05688810A1
• 作为产物：
  描述：

  N-Boc-2-碘苯胺 在 tris-(dibenzylideneacetone)dipalladium(0) 、 1,1'-bis(di-tertbutylphosphino)ferrocene 、 草酰氯 、 sodium hydride 、 caesium carbonate 、 三乙胺 、 9-硼双环[3.3.1]壬烷 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 、 二甲基亚砜 、 甲苯 、 mineral oil 为溶剂， 反应 40.58h， 生成 1-(tert-butoxycarbonyl)-3-methyl-2,3-dihydro-1H-quinolin-4-one
  参考文献：
  名称：

  Intramolecular Pd(0)-Catalyzed Reactions of (2-Iodoanilino)-aldehydes: A Joint Experimental–Computational Study

  摘要：

  An extensive joint experimental-computational density functional theory (DFT) study has been carried out to gain insight into the factors that control the chemoselectivity (i.e., acylation vs alpha-arylation reaction) of palladium-catalyzed cyclizations of (2-iodoanilino)-aldehydes. To this end, the nature of the tethers joining the aniline nitrogen and the aldehyde moiety, different palladium precatalysts and reaction conditions (base and temperature), as well as different additives (mono- and bidendate ligands) has been explored. The adequate selection of these variables allows for the control of the selectivity of the process. Thus, (2-iodoanilino)-aldehydes generally lead to the formation of nucleophilic addition derived products when Cs2CO3/Et3N is used as base. In contrast, the use of stronger bases like (KOBu)-O-t (in the presence of PhOH) mainly forms alpha-arylation reaction products. The different reaction pathways leading to the experimentally observed reaction products have been studied by means of computational tools.

  DOI：

  10.1021/jo301924e

文献信息

• Tricyclic steroid receptor modulator compounds and methods
  申请人：Ligand Pharmaceuticals Incorporated

  公开号：US05696130A1

  公开（公告）日：1997-12-09

  Non-steroidal compounds which are high affinity, high selectivity modulators for steroid receptors are disclosed. Also disclosed are pharmaceutical compositions incorporating such compounds, methods for employing the disclosed compounds and compositions for treating patients requiring steroid receptor agonist or antagonist therapy, intermediates useful in the preparation of the compounds and processes for the preparation of the steroid receptor modulator compounds.

  披露了对类固醇受体具有高亲和力、高选择性调节剂的非类固醇化合物。还披露了包含这些化合物的药物组合物、使用所披露的化合物和组合物治疗需要类固醇受体激动剂或拮抗剂治疗的患者的方法，以及在制备这些化合物中有用的中间体和制备类固醇受体调节剂化合物的过程。
• Intermediates for preparation of steroid receptor modulator compounds
  申请人：Ligand Pharmaceuticals Incorporated

  公开号：US06121450A1

  公开（公告）日：2000-09-19

  Non-steroidal compounds which are high affinity, high selectivity modulators for steroid receptors are disclosed. Also disclosed are pharmaceutical compositions incorporating such compounds, methods for employing the disclosed compounds and compositions for treating patients requiring steroid receptor agonist or antagonist therapy, intermediates useful in the preparation of the compounds and processes for the preparation of the steroid receptor modulator compounds.

  本发明公开了高亲和力、高选择性的非甾体化合物，用于调节甾体受体。还公开了包括这些化合物的药物组合物，以及使用这些化合物和组合物治疗需要甾体受体激动剂或拮抗剂治疗的患者的方法，还公开了制备这些甾体受体调节剂化合物的中间体和制备过程。
• Methods for the preparation of coumarine derivatives
  申请人：LIGAND PHARMACEUTICALS INCORPORATED

  公开号：EP1041071A1

  公开（公告）日：2000-10-04

  Non-steroidal compounds which are high affinity, high selectivity modulators for steroid receptors are disclosed. Also disclosed are pharmaceutical compositions incorporating such compounds, methods for employing the disclosed compounds and compositions for treating patients requiring steroid receptor agonist or antagonist therapy, intermediates useful in the preparation of the compounds and processes for the preparation of the steroid receptor modulator compounds.

  本发明公开了对类固醇受体具有高亲和力、高选择性调节作用的非类固醇化合物。还公开了含有此类化合物的药物组合物、使用所公开化合物和组合物治疗需要类固醇受体激动剂或拮抗剂治疗的患者的方法、制备化合物时有用的中间体以及制备类固醇受体调节剂化合物的工艺。
• STEROID RECEPTOR MODULATOR COMPOUNDS AND METHODS
  申请人：LIGAND PHARMACEUTICALS, INC.

  公开号：EP0800519A1

  公开（公告）日：1997-10-15
• US5688808A
  申请人：——

  公开号：US5688808A

  公开（公告）日：1997-11-18